drugset
drugset / Trial / NCT00686010

Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

NCT00686010 ↗

Phase 2 Completed 198 enrolled Japan Tobacco Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the effect of JTT-705 doses from 300 mg to 900 mg on the elevation of HDL-C and on the inhibition of CETP activity versus placebo, in patients presenting with mild dyslipidaemia. These objectives will be tested after 4 weeks of treatment.

Timeline

Start
2000-05
Primary completion
2001-01
Completion
2001-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalcetrapib Small molecule 300 mg Oral
Subject Dalcetrapib Small molecule 600 mg Oral
Subject Dalcetrapib Small molecule 900 mg Oral

Indications

hyperlipidemia